Press coverage about Cellectar Biosciences (NASDAQ:CLRB) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 48.2641232773629 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Cellectar Biosciences (NASDAQ:CLRB) traded down $0.06 on Tuesday, reaching $1.25. 890,900 shares of the company’s stock traded hands, compared to its average volume of 310,140. Cellectar Biosciences has a 1-year low of $1.06 and a 1-year high of $3.07. The firm has a market capitalization of $19.93, a P/E ratio of -1.17 and a beta of 0.97.
Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). research analysts predict that Cellectar Biosciences will post -0.96 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Cellectar Biosciences (CLRB) Given Media Sentiment Rating of 0.05” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/01/09/cellectar-biosciences-clrb-given-media-sentiment-rating-of-0-05.html.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.